Dahua Technology Unveils Full-color Cube to Explore New Possibilities of Innovation
19.4.2023 15:45:00 EEST | Business Wire | Press release
Dahua Technology, a world-leading video-centric AIoT solution and service provider, unveils the 2023 Full-color Cube concept —— a cube of color magic that combines Full-color, Smart Dual Light and other technologies into infinite possibilities of innovation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230419005078/en/
For years, Dahua has been investing in Full-color Technology that assures users 24/7 colorful monitoring as well as trust-worthy performance in terms of clarity, definition, flexibility, accuracy and intelligence. This year, meet Full-color Cube! It integrates Full-color and Smart Dual Light with other technologies, creating infinite possibilities for innovation and allowing you to do more than you could ever imagine. (Photo: Business Wire)
“Dahua’s Full-color technology is continuously being upgraded, with the addition of Smart Dual Light as one great example. This year, we combined these two core technologies with AI, Duo and PT cameras, as well as other technologies to offer the Full-color Cube that further addresses users’ monitoring needs for vivid and color images in low-light environments,” said Eaden Xie, Product Manager at Dahua Technology.
Featuring panoramic vision, more personalized and flexible settings, intelligence at will, and future growth, the Full-color Cube unlocks a wealth of cutting-edge security functions through strong technological combinations.
Full-color + Panoramic: seamless 180° wide-angle image
The Full-color Panoramic series achieves a wider range of vision coverage by utilizing the capabilities of both Full-color Duo and PT cameras.
- Full-color + Duo
Based on Dahua’s advanced pixel-level metadata fusion algorithm, Full-color Duo camera adopts Dual F1.0 Aperture Lens and Dual 1/1.8" CMOS Sensors to create better imaging effects in low-light conditions. Compared with traditional cameras, its seamless 180° image significantly saves equipment and installation costs. Also, the eyeball model supports 3-axis rotation, which makes installation and operation more convenient. Moreover, its EPTZ function features panoramic image with multiple target details.
- Full-color + PT
Equipped with larger pan & tilt angle, Full-color PT camera provides an expanded field of view with fewer blind spots, while capturing 24/7 color images for more information and details. A variety of mounting brackets makes it easy to install on a pole, ceiling, or wall.
TiOC: full-time protection before, during, and after an event
TiOC (Three-in-One Camera) is a star product of the Dahua Full-color family that integrates Smart Dual Light, Active Deterrence, and AI. Before the event, SMD 4.0 and Perimeter Protection technology accurately focuses on human and vehicle alarms. During the event, Smart Dual Light technology records events in color, while actively deterring intruders with red and blue lights and siren. After the event, Smart Search quickly retrieves target footages, reducing investigation time. TiOC also allows third-party platform access for live broadcast/playback, video and audio parameter configuration, etc.
For more details about Full-color Cubes, please visit here .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005078/en/
Contact information
Zoe Xu (xu_shuyi@dahuatech.com )
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 12:00:00 EEST | Press release
The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport. Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders. World-class, immersive events will unfold across fourteen ic
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 12:00:00 EEST | Press release
Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.2 “Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom